Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Hematology | Family Medicine
Disease Category: Anemia
Location: United States, FL

Clinical Trial Details


Research Study Summary

Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in subjects with NDD-CKD
To Learn more

CW ID: 222916
Date Last Changed: February 3, 2017

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Lead Sponsor
Akebia Therapeutics
Facility Type


Inclusion Criteria:
  • =18 years of age
  • Diagnosis of CKD with an eGFR =60 mL/min/1.73 m^2 at Screening and not expected to start dialysis within 6 months of Screening
  • Currently maintained on ESA therapy, with the last dose received within 8 weeks prior to Screening
  • Mean Screening HGB between 8.0 and 11.0 g/dL (inclusive) in the US and between 9.0 and 12.0 g/dL (inclusive) outside of the US

    Exclusion Criteria:

  • Uncontrolled hypertension
  • Severe heart failure at Screening (New York Heart Association Class IV)
  • Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), urgent coronary revascularization, hospitalization for CHF, or stroke within 12 weeks prior to Screening
  • Contact

    Michele Laney
    University of South Florida - Morsani Center for Advanced Healthcare
    13330 USF Laurel Dr
    Tampa, FL 33612
    Phone: (813) 396-9179

    View Map

    DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.